CHOKSILA.BO · BSE
CHOKSI LABORATORIES LTD.
₹204.85
+3.83% (+₹7.55)
Prev. close
₹197.3
Volume
4,166
As of
BSE · may be slightly delayed · 13:50 IST
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About CHOKSI LABORATORIES LTD.
Choksi Laboratories Limited provides contract testing and analytical services in India. The company offers construction material analysis; environmental management analysis, such as ambient and indoor air quality monitoring, fugitive emissions, stack emission monitoring, soil testing, waste water testing, sound level monitoring, and illumination survey; calibration services comprising electro technical, thermal, dimension, pressure, mass and volume, torque and force, medical devices, and flow meters; and autoclave validation and HVAC system, laminar air flow, equipment qualification, and warehousing mapping for temperature and humidity. It also provides food and beverage, pharmaceutical, and water analysis, as well as inspection services. In addition, the company offers research and quality control services for various spectrum of products and material, including pharmaceutical raw materials and formulations, agro products and derivatives, disinfectants / sanitizers, fertilizers, pesticides and agrochemicals, edible and industrial oils, chemicals, paints and dyes, toys, construction materials, etc.; and ISO 900x, ISO 14000, ISO/IEC 17025, GxP, HACCP, etc. Choksi Laboratories Limited was founded in 1982 and is based in Indore, India.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Sunil Kumar Choksi
Headquarters
Indore
Employees
364
Website
choksilab.inExchange
View on BSE ↗Key stats
Market cap
₹137.42 Cr
P/E ratio (TTM)
63.4
EPS (TTM)
₹3.11
Beta (1Y · daily vs NIFTY 50)
0.40
Beta (5Y · monthly vs NIFTY 50)
0.55
Shares float
30.85 L
EPS · quarter ended Jun 2026
₹0.84
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹25.69 Cr | ₹30.04 Cr | ₹34.44 Cr | ₹36.70 Cr | ₹41.78 Cr | ₹46.01 Cr | |
| EBITDA | ₹4.61 Cr | ₹9.00 Cr | ₹12.71 Cr | ₹10.38 Cr | ₹11.31 Cr | ₹13.11 Cr |
| ₹-2.61 Cr | ₹20.70 L | ₹3.21 Cr | ₹1.11 Cr | ₹1.52 Cr | ₹1.96 Cr | |
| Diluted EPS | ₹-3.74 | ₹0.3 | ₹4.61 | ₹1.59 | ₹2.19 | ₹2.82 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹60.36 Cr | ₹61.95 Cr | ₹65.33 Cr | ₹71.92 Cr | |
| — | — | ₹32.42 Cr | ₹30.87 Cr | ₹29.16 Cr | ₹34.17 Cr | |
| Stockholders' equity | — | — | ₹21.11 Cr | ₹22.21 Cr | ₹23.60 Cr | ₹25.58 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹8.25 Cr | ₹11.55 Cr | ₹11.78 Cr | ₹7.86 Cr | |
| Investing cash flow | — | — | ₹-70.84 L | ₹-6.65 Cr | ₹-7.61 Cr | ₹-7.07 Cr |
| — | — | ₹-7.61 Cr | ₹-4.58 Cr | ₹-4.22 Cr | ₹-1.20 Cr | |
| Capital expenditure | — | — | ₹-4.15 Cr | ₹-7.09 Cr | ₹-7.69 Cr | ₹-8.18 Cr |
| End cash position | — | — | ₹33.75 L | ₹65.69 L | ₹61.23 L | ₹20.67 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| CHOKSI LABORATORIES LTD. | ₹133.25 Cr | ₹191.3 | 61.5 | 5.21 | 7.7% | 1.34 | +10.1% | +1.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 29
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.